Hereditary Angioedema Therapeutics Market Size, Share & Trends Report

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-3-68038-156-6
Number of Pages: 100
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Hereditary Angioedema Therapeutic Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- C1-esterase inhibitor
- Bradykinin B2 receptor antagonist
- Kallikrein inhibitor
- Others
Hereditary Angioedema Therapeutic End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Prophylaxis
- On-demand
Hereditary Angioedema Therapeutic Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Intravenous
- Subcutaneous
- Oral
Hereditary Angioedema Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - C1-esterase inhibitor
    - Bradykinin B2 receptor antagonist
    - Kallikrein inhibitor
    - Others
  - North America Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Prophylaxis
    - On-demand
  - North America Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Subcutaneous
    - Oral
  - U.S.
    - U.S. Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - U.S. Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - U.S. Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Canada
    - Canada Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Canada Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Canada Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
- Europe
  - Europe Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - C1-esterase inhibitor
    - Bradykinin B2 receptor antagonist
    - Kallikrein inhibitor
    - Others
  - Europe Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Prophylaxis
    - On-demand
  - Europe Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Subcutaneous
    - Oral
  - UK
    - UK Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - UK Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - UK Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Germany
    - Germany Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Germany Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Germany Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - France
    - France Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - France Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - France Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Italy
    - Italy Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Italy Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Italy Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Spain
    - Spain Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Spain Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Spain Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Sweden
    - Sweden Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Sweden Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Sweden Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Norway
    - Norway Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Norway Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Norway Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Denmark
    - Denmark Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Denmark Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Denmark Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
- Asia Pacific
  - Asia Pacific Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - C1-esterase inhibitor
    - Bradykinin B2 receptor antagonist
    - Kallikrein inhibitor
    - Others
  - Asia Pacific Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Prophylaxis
    - On-demand
  - Asia Pacific Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Subcutaneous
    - Oral
  - Japan
    - Japan Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Japan Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Japan Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - China
    - China Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - China Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - China Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - India
    - India Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - India Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - India Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Australia
    - Australia Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Australia Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Australia Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Thailand
    - Thailand Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Thailand Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Thailand Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - South Korea
    - South Korea Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - South Korea Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - South Korea Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
- Latin America
  - Latin America Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - C1-esterase inhibitor
    - Bradykinin B2 receptor antagonist
    - Kallikrein inhibitor
    - Others
  - Latin America Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Prophylaxis
    - On-demand
  - Latin America Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Subcutaneous
    - Oral
  - Brazil
    - Brazil Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Brazil Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Brazil Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Mexico
    - Mexico Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Mexico Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Mexico Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Argentina
    - Argentina Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Argentina Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Argentina Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
- Middle East and Africa
  - Middle East and Africa Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - C1-esterase inhibitor
    - Bradykinin B2 receptor antagonist
    - Kallikrein inhibitor
    - Others
  - Middle East and Africa Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Prophylaxis
    - On-demand
  - Middle East and Africa Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Intravenous
    - Subcutaneous
    - Oral
  - South Africa
    - South Africa Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - South Africa Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - South Africa Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Saudi Arabia
    - Saudi Arabia Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Saudi Arabia Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Saudi Arabia Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - UAE
    - UAE Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - UAE Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - UAE Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral
  - Kuwait
    - Kuwait Hereditary Angioedema Therapeutic Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - C1-esterase inhibitor
      - Bradykinin B2 receptor antagonist
      - Kallikrein inhibitor
      - Others
    - Kuwait Hereditary Angioedema Therapeutic Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Prophylaxis
      - On-demand
    - Kuwait Hereditary Angioedema Therapeutic Market, Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Intravenous
      - Subcutaneous
      - Oral

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.